Form 4: aTyr Pharma Director Jane A. Gross Acquires 24,000 Stock Options
SEC Form 4 Filing
Director Jane A. Gross acquired 24,000 stock options in aTyr Pharma Inc. on May 22, 2024, according to a Form 4 filing with the SEC.
Summary
- Jane A. Gross, a director of aTyr Pharma Inc., acquired 24,000 stock options on May 22, 2024.
- The options have an exercise price of $1.86.
- These options were granted pursuant to the Issuer's non-employee director compensation policy.
- The options vest fully on the earlier of May 22, 2025, or the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service on the Board of Directors.
- Following the transaction, Ms. Gross directly owns 24,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock option grants, which is neutral in sentiment.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of transaction: Jane A. Gross acquired 24,000 stock options. |
| 05/22/2025 | Earliest vesting date for the stock options, contingent on continued service. |
| 05/22/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.